OBJECTIVE: To determine the association of smoking and HIV status with tissue-specific inflammation measured by flurodeoxyglucose positron emission tomography (PET). DESIGN: A cross-sectional study. METHODS: We prospectively enrolled 55 HIV study participants on stable antiretroviral therapy and 19 age-matched HIV-uninfected controls without known cardiovascular disease. We measured aortic target-to-background ratio (TBR) and spleen standardized uptake values (SUV) 3-h post-FDG, and used regression models to examine the independent association of HIV and smoking status with PET variables. RESULTS: Overall, median (interquartile range) age was 50 (42-55) years; 81% were men and 54% were current smokers (median 0.5 packs/day, 25 pack-years]. Median CD4 of HIV study participants was 690 cells/ml and 88% had HIV-1 RNA less than 20 c/ml; 43% were on a protease inhibitor. In fully adjusted models, HIV was associated with 0.16 (95% confidence interval 0.04-0.27; P = 0.009) higher aortic TBR, whereas current smoking was marginally associated with a lower TBR [-0.11 (95% confidence interval -0.23 to 0.01); P = 0.07]. Spleen SUVmean was not associated with HIV or smoking, and there was no evidence for an HIVsmoking interaction for aortic or spleen models (all P > 0.1). Spleen SUVmean was positively associated with biomarkers of inflammation and coronary artery calcium, but adjustment for traditional cardiovascular disease risk factors attenuated these relationships. CONCLUSION: The FDG-PET study of HIV study participants suggests that HIV is associated with increased aortic inflammation independent of traditional risk factors, but smoking is not. Future studies should continue to explore the mechanistic roles of smoking and inflammation at various stages of clinical and subclinical atherosclerotic vascular disease in HIV.
OBJECTIVE: To determine the association of smoking and HIV status with tissue-specific inflammation measured by flurodeoxyglucose positron emission tomography (PET). DESIGN: A cross-sectional study. METHODS: We prospectively enrolled 55 HIV study participants on stable antiretroviral therapy and 19 age-matched HIV-uninfected controls without known cardiovascular disease. We measured aortic target-to-background ratio (TBR) and spleen standardized uptake values (SUV) 3-h post-FDG, and used regression models to examine the independent association of HIV and smoking status with PET variables. RESULTS: Overall, median (interquartile range) age was 50 (42-55) years; 81% were men and 54% were current smokers (median 0.5 packs/day, 25 pack-years]. Median CD4 of HIV study participants was 690 cells/ml and 88% had HIV-1 RNA less than 20 c/ml; 43% were on a protease inhibitor. In fully adjusted models, HIV was associated with 0.16 (95% confidence interval 0.04-0.27; P = 0.009) higher aortic TBR, whereas current smoking was marginally associated with a lower TBR [-0.11 (95% confidence interval -0.23 to 0.01); P = 0.07]. Spleen SUVmean was not associated with HIV or smoking, and there was no evidence for an HIVsmoking interaction for aortic or spleen models (all P > 0.1). Spleen SUVmean was positively associated with biomarkers of inflammation and coronary artery calcium, but adjustment for traditional cardiovascular disease risk factors attenuated these relationships. CONCLUSION: The FDG-PET study of HIV study participants suggests that HIV is associated with increased aortic inflammation independent of traditional risk factors, but smoking is not. Future studies should continue to explore the mechanistic roles of smoking and inflammation at various stages of clinical and subclinical atherosclerotic vascular disease in HIV.
Authors: Markella V Zanni; Mabel Toribio; Gregory K Robbins; Tricia H Burdo; Michael T Lu; Amorina E Ishai; Meghan N Feldpausch; Amanda Martin; Kathy Melbourne; Virginia A Triant; Sujit Suchindran; Hang Lee; Udo Hoffmann; Kenneth C Williams; Ahmed Tawakol; Steven K Grinspoon Journal: JAMA Cardiol Date: 2016-07-01 Impact factor: 14.676
Authors: Ahmed Tawakol; Amorina Ishai; Danny Li; Richard A P Takx; Sophia Hur; Yannick Kaiser; Miguel Pampaloni; Adam Rupert; Denise Hsu; Irini Sereti; Rémi Fromentin; Nicolas Chomont; Peter Ganz; Steven G Deeks; Priscilla Y Hsue Journal: JAMA Cardiol Date: 2017-02-01 Impact factor: 14.676
Authors: Line D Rasmussen; Marie Helleberg; Margaret T May; Shoaib Afzal; Gitte Kronborg; Carsten S Larsen; Court Pedersen; Jan Gerstoft; Børge G Nordestgaard; Niels Obel Journal: Clin Infect Dis Date: 2015-01-16 Impact factor: 9.079
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Am Coll Cardiol Date: 2007-08-13 Impact factor: 24.094
Authors: Amparo L Figueroa; Amr Abdelbaky; Quynh A Truong; Erin Corsini; Megan H MacNabb; Zachary R Lavender; Meredith A Lawler; Steven K Grinspoon; Thomas J Brady; Khurram Nasir; Udo Hoffmann; Ahmed Tawakol Journal: JACC Cardiovasc Imaging Date: 2013-10-23
Authors: Hamed Emami; Parmanand Singh; Megan MacNabb; Esad Vucic; Zachary Lavender; James H F Rudd; Zahi A Fayad; Joshua Lehrer-Graiwer; Magnus Korsgren; Amparo L Figueroa; Jill Fredrickson; Barry Rubin; Udo Hoffmann; Quynh A Truong; James K Min; Amos Baruch; Khurram Nasir; Matthias Nahrendorf; Ahmed Tawakol Journal: JACC Cardiovasc Imaging Date: 2015-01-07
Authors: Jonathan A Hudson; Edith D Majonga; Rashida A Ferrand; Pablo Perel; Shirjel R Alam; Anoop S V Shah Journal: JAMA Date: 2022-09-13 Impact factor: 157.335
Authors: Charalambos V Vlachopoulos; Iosif P Koutagiar; Alexandros T Georgakopoulos; Anastasia G Pouli; Anastasia Κ Sioni; Stavroula Ε Giannouli; Spiros D Chondropoulos; Ioanna Ε Stergiou; Eirini G Solomou; Dimitrios G Terentes-Printzios; Ioannis G Karakitsios; Pavlos P Kafouris; Anastasios Gaitanis; Nikoletta K Pianou; Aikaterini Petrocheilou; Constantina I Aggeli; Euaggelia Stroumpouli; Theodoros P Marinakis; Michael Voulgarelis; Dimitrios M Tousoulis; Constantinos D Anagnostopoulos Journal: JACC CardioOncol Date: 2020-12-15
Authors: Scott E Janus; Claire Sullivan; Justin Morrison; Grace A McComsey; Chris T Longenecker Journal: J Acquir Immune Defic Syndr Date: 2020-03-01 Impact factor: 3.771